Tag:

Eli Lilly

Latest Headlines

Latest Headlines

AstraZeneca adds Lilly to its stable of immuno-oncology collaborators

AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.

Lilly and Zealand scrap diabetes, obesity R&D collaboration

Eli Lilly and Zealand Pharma have scrapped their diabetes and obesity-focused R&D collaboration. The companies teamed up in 2013 to explore using novel peptides to treat Type 2 diabetes and obesity, but 21 months later have decided there is no point pursuing the program.

UPDATED: My bathtub or yours? How a panned Cialis ad became promotional gold

Television ads have shown them lounging on a beach, gazing at the view from a mountaintop and watching the view from above a scenic lake. All sans clothing and facing away from the camera. We're talking about Eli Lilly's Cialis bathtub couples, of course. Yet the bathtub couples were not universally well-received at launch, and they've been oft-spoofed since.

Data-gathering insulin pen maker Companion pulls in Series B led by Eli Lilly

Companion Medical, a California startup with a Bluetooth-enabled insulin pen and smartphone app, pulled in Series B financing this week, led by Big Pharma player Eli Lilly. Though the amount was undisclosed, the move marks a step forward for Lilly into the world of drug delivery technology, for which the company is currently building an R&D center in Cambridge, MA.

BioNTech strikes back-to-back immuno-oncology deals with Lilly and Genmab

BioNTech has snagged a small upfront fee to enter into an immuno-oncology co-development pact with Genmab. The deal was unveiled one week after Eli Lilly invested $30 million (€27 million) in BioNTech as part of an immuno-oncology deal worth a potential $300 million per asset.

Eli Lilly leads Series B for startup with connected insulin pen, smartphone app combo

Eli Lilly has led a Series B round for San Diego, CA-based startup Companion Medical. The financing is expected to enable the completion of testing and 510(k) submission for its Bluetooth-enabled insulin pen and accompanying smartphone app. The amount of the financing was undisclosed.

Eli Lilly to work with Sanford-Burnham on autoimmune diseases

Eli Lilly has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.

Chi-Med unit slated for $18M in milestones from Lilly

Eli Lilly is set to make an $18 million milestone payment to Hutchison MediPharma, majority owned by Hutchison China MediTech, or Chi-Med, in the second quarter of 2015 after a positive first proof-of-concept study result for fruquintinib, a candidate for treatment of patients with metastatic colorectal cancer in China.

FDA warns Lilly to stop marketing antibiotic for weight gain in pigs

When Eli Lilly bought Novartis Animal Health last year, it picked up a product that the FDA had in its crosshairs: Denagard (tiamulin hydrogen fumarate) plus CTC (chlortetracycline hydrochloride), a medicated feed product for pigs. The product is an antibiotic, and the FDA wants Lilly to stop marketing it for weight gain.

Lucky 7 diabetes meds to join blockbuster club by 2020

Which diabetes med is likely to be on top in 2020? According to FirstWord Pharma, that would be--surprise!--Lantus, albeit as a $5 billion shadow of its former self. Januvia should keep its hold on second prize with almost $4 billion, while Novo Nordisk's NovoRapid and Lilly's Humalog remain in the top 5 with $3.6 billion and $3.04 billion in sales.